Business Wire

First Marketing Authorizations in Europe for IQYMUNE®, LFB’s 10% Liquid Intravenous Immunoglobulin

Del

LFB SA announces the first two marketing authorizations for its 10% liquid intravenous immunoglobulin (IVIg) in Europe, namely in the United Kingdom and in Denmark. Thirteen more national marketing authorizations in Europe are expected in the coming months. Simultaneously to this ongoing European decentralized procedure, registrations are to take place in 33 countries in rest of the world, for launches staggered between 2016 and 2020.

Since 26 th August 2015, LFB’s “new generation” 10% liquid IVIg has been registered in the United Kingdom and in Denmark since 4 th September, in the Core SmPC indications. This immunoglobulin has a high-level of purity, relying namely on an innovative manufacturing process developed by LFB for its liquid immunoglobulins.

For rare immune system disorders. LFB’s 10% liquid IVIg IQYMUNE® will allow clinicians to treat rare immunity disorders, mostly hereditary, such as Primary Immunodeficiencies, Immunologic Thrombocytopenic Purpura, Guillain-Barré syndrome and Kawasaki disease, and acquired conditions such as Secondary Immunodeficiency. These diseases concern dozens of thousands of people in Europe, calling for chronic care most of the time.

Immunoglobulins being more and more prescribed in rare and severe dysimmunitary neuropathic affections, LFB conducts two Phase III clinical trials in Europe in order to register IQYMUNE® in the indications of MMN and CIDP1, two severe dysimmunitary neuropathic diseases.

Registration on the way in 15 European countries. LFB chose a decentralized procedure for European registration, with the German Paul Ehrlich Institute (PEI) as the referent authority for the procedure. Following the United Kingdom and Denmark, registration for IQYMUNE® is expected in the following European countries: Austria, Germany, Belgium, Spain, Finland, Greece, Hungary, Italy, Luxemburg, the Netherlands, the Czech Republic, Slovakia and Sweden.

LFB reinforces its positions in Immunology. “The registrations for IQYMUNE® in Europe and in 33 countries are to contribute to LFB group’s rapidly growing international activity, with LFB currently making a third of its turnover with international business” points out Christian Béchon, CEO of the LFB group. “Given the increasing global demand in immunoglobulins, the launch of our 10% liquid IVIg, to start in 2016, is of strategic importance” adds Mr. Béchon. The registration of IQYMUNE® in many European countries is also a major milestone for LFB’s research and development policy, particularly active in the field of Immunology. “With two current phases III on IQYMUNE®, and the first anti-D monoclonal antibody under clinical trials (phase II b) in the world, for the prevention of hemolytic disease of the newborn, we have major developments to achieve in the coming years” stresses out Guillaume Bologna, General Manager Development for the LFB group.

IQYMUNE® is to represent as much as 9 tons capacity in 2025, thanks to additional manufacturing capacities with upcoming new fractionation plant in France (city of Arras) that is to start around 2020.

1 MMN: Multifocal Motor Neuropathy; CIDP: Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

About the LFB group . The LFB group ( www.lfb.fr ) is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.
The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group markets its products in more than 40 countries around the world with a global turnover of € 501, 9 million in 2014. www.lfb.fr

Follow the LFB group on the social networks

https://twitter.com/LFB_Group

http://www.linkedin.com/company/lfb

https://www.youtube.com/channel/UCyqRqdG_TaU9ZckG9RaxKzA

Contact information

LFB S.A
Sandrine Charrières – Executive VP Corporate Communications
Phone: +33 (1) 69 82 72 80
email: charrieres@lfb.fr
or
Media relations
Jeanne Bariller
Havas Worldwide
Phone: +33 (6) 15 51 49 40
email: jeanne.bariller@havasww.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares19.2.2018 18:19Pressemelding

Zonoville Investments Limited, a consortium of investors led by Renova Group and Access Industries, announced today that it had reached an agreement with Onexim Group to purchase its 6% stake in the United Company RUSAL Plc. Following completion of the purchase, Zonoville Investments Limited and its associate SUAL Partners Limited will hold, in aggregate, approximately a 26.5% interest in United Company RUSAL Plc. About Renova Renova Group of companies (www.renova.ru) is a major private Russian business group which owns and manages assets in metallurgy, mining, chemical, construction, transport, energy, telecommunications, high-tech engineering, public utilities, medicine and financial sectors in Russia and abroad (CIS, Switzerland, Italy, South Africa and the United States of America). Renova’s largest assets include its interests in UC Rusal, T Plus Group, OCTO Telematics and Swiss-based technology concerns Schmolz+Bickenbach, OC Oerlikon, and Sulzer. About Access Industries Founded

The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London19.2.2018 18:05Pressemelding

Medical innovation will take centre stage for 2018, at the largest wearables and disruptive health technology event in the world, with never before-seen devices and applications and a raft of industry-leading speakers. The Digital Health Technology Show returns to London on the 13th & 14th March 2018 at London’s Excel, gathering together more than 6,000 attendees and over 100 exhibitors. The 2018 Conference programme boasts three tracks, with over 100 hours of content programmed. Attendees can choose to attend talks on the Digital Health Disrupt Stage – covering global innovation in healthcare, the Leadership Theatre – where senior healthcare figures in the UK will discuss and debate the challenges ahead, or the Patient Engagement Stage – delivering insights into how technology is being used in the real world. There will also be demonstrations of the latest medical innovations on the Innovation Stage, which will also host a start up competition – The Health Innovation Award. Over 200 s

World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London19.2.2018 13:00Pressemelding

The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/ Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire) The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based pro

Tampere Attracts AV Productions with a New Incentive19.2.2018 12:41Pressemelding

One of the City of Tampere’s strategic goals is to be an international meeting place for creativity and innovation. The development of the experience economy is an essential focus of the city’s business policy. The incentive system is being used to attract more local, national and international productions to the Tampere region. The goal is to promote the development of the industry and to increase the number of jobs and the turnover of commercial productions in Tampere. Through the incentive system, an audiovisual production may recover some of the costs it has spent on wages and service purchases in the Tampere region. A production meeting the incentive criteria may be refunded 10–15 per cent of the accepted costs accrued in the region. Professional productions that utilise the Tampere region as their location or use expertise from the area may apply for the incentive. Thanks to the growing number of productions, Tampere will become more visible in films and TV shows, which will add

Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14Pressemelding

Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an

Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 10:05Pressemelding

Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping